Amneal Pharmaceuticals, Inc. financial data

Symbol
AMRX on Nasdaq
Industry
Pharmaceutical Preparations
Location
400 Crossing Boulevard, 3 Rd Floor, Bridgewater, NJ
Fiscal year end
December 31
Former names
Atlas Holdings, Inc. (to 4/13/2018)
Latest financial report
10-K - Q4 2024 - Feb 28, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 143 % -20.6%
Quick Ratio 56.4 % -22.1%
Return On Equity 369 % +21792%
Return On Assets -5.17 % -7379%
Operating Margin 8.92 % +4.57%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 310M shares
Entity Public Float 1.6B USD +245%
Weighted Average Number of Shares Outstanding, Basic 309M shares +75.4%
Weighted Average Number of Shares Outstanding, Diluted 309M shares +75.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 2.79B USD +16.7%
Research and Development Expense 191M USD +16.3%
Operating Income (Loss) 249M USD +22%
Nonoperating Income (Expense) -304M USD -24.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -55M USD -36.6%
Income Tax Expense (Benefit) 18.9M USD +123%
Net Income (Loss) Attributable to Parent -180M USD -6934%
Earnings Per Share, Basic -0.38 USD/shares +20.8%
Earnings Per Share, Diluted -0.38 USD/shares +20.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 111M USD +20.8%
Accounts Receivable, after Allowance for Credit Loss, Current 546M USD +1.38%
Inventory, Net 612M USD +5.34%
Assets, Current 1.59B USD +15.2%
Property, Plant and Equipment, Net 425M USD -5.06%
Operating Lease, Right-of-Use Asset 42.4M USD -2.15%
Intangible Assets, Net (Excluding Goodwill) 732M USD -17.8%
Goodwill 597M USD -0.2%
Other Assets, Noncurrent 60.1M USD +8.32%
Assets 3.5B USD +0.83%
Accounts Payable, Current 235M USD +32.5%
Employee-related Liabilities, Current 64.9M USD +22.9%
Liabilities, Current 1.13B USD +33.4%
Other Liabilities, Noncurrent 41.5M USD +26.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax -65.5M USD -103%
Retained Earnings (Accumulated Deficit) -607M USD -23.8%
Stockholders' Equity Attributable to Parent -109M USD -652%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -110M USD -647%
Liabilities and Equity 3.5B USD +0.83%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.41M USD -103%
Net Cash Provided by (Used in) Financing Activities -23.2M USD -79.5%
Net Cash Provided by (Used in) Investing Activities -19.8M USD -68.4%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -47.5M USD -141%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 118M USD +19.5%
Interest Paid, Excluding Capitalized Interest, Operating Activities 64.5M USD +57.1%
Deferred Tax Assets, Valuation Allowance 590M USD +4.2%
Deferred Tax Assets, Gross 590M USD +4.2%
Operating Lease, Liability 47M USD -3.84%
Payments to Acquire Property, Plant, and Equipment 9.2M USD -5.06%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -150M USD -18.1%
Lessee, Operating Lease, Liability, to be Paid 58.8M USD -4.22%
Property, Plant and Equipment, Gross 988M USD +3.44%
Lessee, Operating Lease, Liability, to be Paid, Year Two 13.5M USD -7.21%
Lessee, Operating Lease, Liability, to be Paid, Year One 16.9M USD +5.86%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure +11.2%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 11.7M USD -5.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 10.6M USD -1.22%
Deferred Tax Assets, Operating Loss Carryforwards 33.4M USD -55.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 2M shares 0%
Unrecognized Tax Benefits 3.94M USD +5.6%
Lessee, Operating Lease, Liability, to be Paid, Year Four 8.2M USD +5.85%
Additional Paid in Capital 560M USD +3.89%
Amortization of Intangible Assets 174M USD +6.37%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%